title: Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer.
abstract: OBJECTIVE
  Osteoporosis causes morbidity and mortality in men. The National Osteoporosis Foundation recommends fracture risk assessment with the online WHO/FRAX tool. Although androgen deprivation therapy for prostate cancer increases fracture risk, there is limited information about which men require preventative drug therapy. We applied the WHO/FRAX tool to men treated with androgen deprivation therapy for prostate cancer.
  
  
  METHODS
  Information was collected from a practice cohort of men treated with gonadotropin-releasing hormone agonists, and included age, height, weight, history of gonadotropin-releasing hormone agonist treatment, dual energy x-ray absorptiometry results, prior bone targeted therapy and clinical risk factors for fracture. Subjects were evaluated with the WHO/FRAX algorithm (http://www.shef.ac.uk/FRAX/).
  
  
  RESULTS
  A total of 363 men treated with androgen deprivation therapy (median age 72 years) were evaluated. By the FRAX algorithm with clinical information (no dual energy x-ray absorptiometry data) the 3% hip fracture risk threshold for treatment was exceeded by 51.2% of the men (median risk 3.1%). When subjects were grouped by age the treatment threshold was reached by 3.3% of those younger than 70 years, 76.6% of those 70 to 79 years old and by 98.8% of those 80 years old or older. Using FRAX with bone mineral density data in the 93 patients who underwent bone mineral density testing the median 10-year hip fracture risk was 0.9% and the treatment threshold was exceeded by 15% of these subjects.
  
  
  CONCLUSIONS
  In this cohort of men receiving androgen deprivation therapy the prevalence of risk sufficient to necessitate drug therapy was high and was strongly influenced by age. The WHO/FRAX algorithm identifies a greater proportion of men for treatment than the traditional threshold of T score -2.5 or less.
authors.affiliation: Division of Hematology-Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. psaylor@partners.org
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Saylor
authors.forename: Donald S
authors.initials: DS
authors.lastname: Kaufman
authors.forename: M Dror
authors.initials: MD
authors.lastname: Michaelson
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Lee
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Smith
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D000726:Androgen Antagonists / Q000009:adverse effects*; D050723:Fractures, Bone / Q000453:epidemiology* / Q000209:etiology* / Q000517:prevention & control; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D018570:Risk Assessment
chemical_list: D000726:Androgen Antagonists; D007987:Gonadotropin-Releasing Hormone
references.citation: J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68
references.pmid: 12359855
references.citation: Osteoporos Int. 2005 Jul;16(7):737-42
references.pmid: 15455194
references.citation: Osteoporos Int. 1997;7(5):407-13
references.pmid: 9425497
references.citation: J Urol. 1999 Apr;161(4):1219-22
references.pmid: 10081873
references.citation: J Bone Miner Res. 2005 Jul;20(7):1185-94
references.pmid: 15940371
references.citation: J Clin Endocrinol Metab. 1999 Oct;84(10):3431-4
references.pmid: 10522975
references.citation: J Urol. 2000 Jan;163(1):181-6
references.pmid: 10604342
references.citation: Osteoporos Int. 2005 Nov;16(11):1330-8
references.pmid: 15928804
references.citation: J Bone Miner Res. 2004 Jun;19(6):893-9
references.pmid: 15125788
references.citation: J Bone Miner Res. 2005 Mar;20(3):494-500
references.pmid: 15746995
references.citation: Osteoporos Int. 2006;17(11):1577-83
references.pmid: 16896511
references.citation: N Engl J Med. 2005 Jan 13;352(2):154-64
references.pmid: 15647578
references.citation: J Clin Oncol. 2003 Aug 15;21(16):3150-7
references.pmid: 12915606
references.citation: J Clin Endocrinol Metab. 2002 Feb;87(2):599-603
references.pmid: 11836291
references.citation: Osteoporos Int. 2008 Apr;19(4):385-97
references.pmid: 18292978
references.citation: Osteoporos Int. 2005 Feb;16(2):155-62
references.pmid: 15175845
references.citation: World Health Organ Tech Rep Ser. 1994;843:1-129
references.pmid: 7941614
references.citation: Osteoporos Int. 2008 Apr;19(4):449-58
references.pmid: 18292975
references.citation: Bone. 2004 Nov;35(5):1029-37
references.pmid: 15542027
references.citation: J Urol. 2006 Jan;175(1):136-9; discussion 139
references.pmid: 16406890
references.citation: Osteoporos Int. 2010 Apr;21(4):647-53
references.pmid: 19533207
references.citation: J Clin Oncol. 2005 Nov 1;23(31):7897-903
references.pmid: 16258089
references.citation: J Clin Densitom. 2008 Oct-Dec;11(4):473-7
references.pmid: 18562228
references.citation: J Bone Miner Metab. 2003;21(1):17-21
references.pmid: 12491089
references.citation: Bone. 2004 Aug;35(2):375-82
references.pmid: 15268886
references.citation: J Urol. 2002 Jun;167(6):2361-7; discussion 2367
references.pmid: 11992038
references.citation: N Engl J Med. 2001 Sep 27;345(13):948-55
references.pmid: 11575286
references.citation: Osteoporos Int. 2005 Jun;16(6):581-9
references.pmid: 15616758